MarketCap
Facebook
X
Telegram
PainReform Ltd. Gesamtes Eigenkapital | PRFX
Gesamtes Eigenkapital Jährlich PainReform Ltd.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.54 M | 1.82 M | 7.24 M | 11 M | 18.1 M | 16.6 M | -12.2 M | -11.1 M | - | - | - | - | - | - | - |
Jährliche Entwicklung
Kennzahlen zur Anzeige auswählen
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 18.1 M | -12.2 M | 5 M |
Gesamtes Eigenkapital Vierteljährlich PainReform Ltd.
| 2025-Q4 | 2025-Q2 | 2024-Q4 | 2024-Q2 | 2023-Q4 | 2023-Q2 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.29 M | 8.44 M | 1.82 M | -2.04 M | 7.24 M | 6.97 M | - | - | - | - | 18.1 M | - | 19 M | - | 16.6 M | - | -14.2 M | - | -12.2 M | - | -11.5 M | - | -11.1 M | - | - | - | -10.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quartalsentwicklung
Kennzahlen zur Anzeige auswählen
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 19 M | -14.2 M | 1.87 M |
Gesamtes Eigenkapital anderer Aktien in der Pharmaeinzelhändler
| Name | Gesamtes Eigenkapital | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
Onconova Therapeutics
ONTX
|
-629 K | - | -0.47 % | $ 21 M |  USA |
 |
Opthea Limited
OPT
|
-201 M | - | - | $ 1.2 B |  Australia |
 |
Verastem
VSTM
|
57.2 M | $ 8.74 | 0.52 % | $ 606 M | USA |
 |
BiomX
PHGE
|
-1.3 M | $ 1.85 | 14.2 % | $ 3.02 M |  Israel |
 |
Pieris Pharmaceuticals
PIRS
|
28 M | - | -15.58 % | $ 1.22 B |  Germany |
 |
Plus Therapeutics
PSTV
|
4 M | - | - | $ 301 M | USA |
 |
Pluristem Therapeutics
PSTI
|
-23 M | - | -1.9 % | $ 33.3 M | Israel |
 |
Qualigen Therapeutics
QLGN
|
28 M | - | 5.59 % | $ 1.16 M | USA |
|
Qilian International Holding Group Limited
QLI
|
391 M | - | -6.08 % | $ 184 M |  China |
 |
Cassava Sciences
SAVA
|
74.4 M | - | - | $ 110 M | USA |
 |
Selecta Biosciences
SELB
|
-126 M | - | -8.69 % | $ 126 M | USA |
 |
Sangamo Therapeutics
SGMO
|
-14.3 M | - | - | $ 50.4 M | USA |
 |
Salarius Pharmaceuticals
SLRX
|
5.89 M | - | - | $ 2.64 M | USA |
 |
Sensei Biotherapeutics
SNSE
|
18.6 M | - | - | $ 17.5 M | USA |
 |
Sonnet BioTherapeutics Holdings
SONN
|
10.8 M | - | - | $ 826 K | USA |
 |
Synthetic Biologics
SYN
|
15.4 M | - | 1.32 % | $ 16.2 M | USA |
 |
Synlogic
SYBX
|
11.9 M | - | - | $ 7.07 M | USA |
 |
Virios Therapeutics, LLC
VIRI
|
74.9 M | - | 2710.01 % | $ 72.9 M | USA |
 |
Vallon Pharmaceuticals
VLON
|
6.01 M | - | -6.47 % | $ 5.76 M | USA |
 |
Vaxart
VXRT
|
94.1 M | - | -25.06 % | $ 46.3 M | USA |
 |
XOMA Corporation
XOMA
|
83.9 M | - | - | $ 485 M | USA |
 |
Repare Therapeutics
RPTX
|
151 M | - | - | $ 112 M |  Canada |
 |
Sesen Bio
SESN
|
-27.9 M | - | 7.29 % | $ 127 M | USA |
|
Windtree Therapeutics
WINT
|
10 M | - | - | $ 26.8 M | USA |
 |
Trean Insurance Group
TIG
|
315 M | - | - | $ 316 M | USA |
 |
SQZ Biotechnologies Company
SQZ
|
57.1 M | - | 57.95 % | $ 12.8 M | USA |
 |
MEI Pharma
MEIP
|
41.6 M | - | 10.43 % | $ 20.5 M | USA |
 |
Palatin Technologies
PTN
|
6.69 M | - | - | $ 13 M | USA |
 |
Lyra Therapeutics
LYRA
|
-10.7 M | - | - | $ 24.9 M | USA |
 |
Brickell Biotech
BBI
|
9.93 M | - | -5.38 % | $ 6.06 M | USA |
 |
Applied Therapeutics
APLT
|
57 M | - | - | $ 8.42 M | USA |
 |
ESSA Pharma
EPIX
|
125 M | - | - | $ 8.86 M | Canada |
 |
Generation Bio Co.
GBIO
|
86.2 M | - | - | $ 344 M | USA |
 |
Clearside Biomedical
CLSD
|
-38.9 M | - | - | $ 25.3 M | USA |
 |
Merus N.V.
MRUS
|
648 M | - | - | $ 5.78 B |  Niderland |
 |
RAPT Therapeutics
RAPT
|
190 M | - | - | $ 2.36 B | USA |
 |
Annexon
ANNX
|
212 M | $ 4.2 | -0.71 % | $ 651 M | USA |
 |
AbbVie
ABBV
|
-3.27 B | $ 293.87 | 0.19 % | $ 520 B | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
789 M | $ 151.6 | -3.2 % | $ 19.9 B | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
15.8 M | $ 4.63 | 21.05 % | $ 20 M | Israel |
 |
Avenue Therapeutics
ATXI
|
1.83 M | - | -52.27 % | $ 4.45 M | USA |
 |
Axon Enterprise
AXON
|
3.24 B | $ 302.6 | -0.19 % | $ 23.6 B | USA |
 |
Theratechnologies
THTX
|
-25.3 M | - | - | $ 83.9 M | Canada |
 |
Liquidia Corporation
LQDA
|
44.7 M | $ 51.37 | 7.31 % | $ 4.42 B | USA |
 |
CRISPR Therapeutics AG
CRSP
|
1.92 B | $ 45.05 | -9.97 % | $ 4.05 B |  Schweiz |
 |
Scholar Rock Holding Corporation
SRRK
|
245 M | $ 48.48 | -5.96 % | $ 5.56 B | USA |